MX2022003128A - Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. - Google Patents

Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Info

Publication number
MX2022003128A
MX2022003128A MX2022003128A MX2022003128A MX2022003128A MX 2022003128 A MX2022003128 A MX 2022003128A MX 2022003128 A MX2022003128 A MX 2022003128A MX 2022003128 A MX2022003128 A MX 2022003128A MX 2022003128 A MX2022003128 A MX 2022003128A
Authority
MX
Mexico
Prior art keywords
methods
patient population
particular patient
neurodegenerative disorders
treating neurodegenerative
Prior art date
Application number
MX2022003128A
Other languages
English (en)
Inventor
Susan Abushakra
Petr Kocis
Martin Tolar
John Hey
Aidan Power
Jeremy Yu
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2022003128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of MX2022003128A publication Critical patent/MX2022003128A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aquí se describen métodos para tratar, mejorar y/o prevenir la enfermedad de Alzheimer en una población de pacientes específica utilizando tramiprosato, ácido valil-3-amino-1-propansulfónico o una sal farmacéuticamente aceptable del mismo basado en una combinación de estado APOE4 y gravedad de la enfermedad.
MX2022003128A 2015-09-10 2018-03-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular. MX2022003128A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
MX2022003128A true MX2022003128A (es) 2022-08-02

Family

ID=58240195

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003023A MX2018003023A (es) 2015-09-10 2016-09-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
MX2022003128A MX2022003128A (es) 2015-09-10 2018-03-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003023A MX2018003023A (es) 2015-09-10 2016-09-09 Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.

Country Status (21)

Country Link
US (3) US11191742B2 (es)
EP (2) EP4275750A3 (es)
JP (3) JP6789579B2 (es)
KR (2) KR102412997B1 (es)
CN (3) CN108289870A (es)
AU (1) AU2016319107B2 (es)
CA (1) CA2997376C (es)
DK (1) DK3347002T3 (es)
ES (1) ES2952727T3 (es)
FI (1) FI3347002T3 (es)
HK (1) HK1257874A1 (es)
HR (1) HRP20230809T1 (es)
HU (1) HUE062511T2 (es)
LT (1) LT3347002T (es)
MD (1) MD3347002T2 (es)
MX (2) MX2018003023A (es)
PL (1) PL3347002T3 (es)
PT (1) PT3347002T (es)
RS (1) RS64481B1 (es)
SI (1) SI3347002T1 (es)
WO (1) WO2017044840A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143447A2 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
CN114805211A (zh) 2017-03-21 2022-07-29 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
AU2019314323A1 (en) * 2018-08-01 2021-03-18 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
SG11202100767XA (en) * 2018-08-01 2021-02-25 Alzheon Inc Methods for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CA3144008A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
WO2023107658A1 (en) * 2021-12-09 2023-06-15 Alzheon, Inc. Alz-801 for use in treating alzheimer's disease
WO2023150381A1 (en) * 2022-02-07 2023-08-10 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ATE262592T1 (de) 1992-10-13 2004-04-15 Univ Duke Verfahren zum nachweis der alzheimer krankheit
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
JP2007502418A (ja) 2003-08-11 2007-02-08 カリフォルニア・インスティテュート・オブ・テクノロジー 微量流体大規模集積
WO2007069073A2 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
PL3851447T3 (pl) 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
CN102838532A (zh) 2006-11-24 2012-12-26 Ac免疫有限公司 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
US10449177B2 (en) 2010-08-19 2019-10-22 Buck Institute For Research On Aging Methods of treating mild cognitive impairment (MCI) and related disorders
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
KR20230056800A (ko) * 2014-02-08 2023-04-27 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
WO2015143447A2 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population

Also Published As

Publication number Publication date
EP4275750A3 (en) 2024-01-17
JP2018526407A (ja) 2018-09-13
DK3347002T3 (da) 2023-08-14
HK1257874A1 (zh) 2019-11-01
KR20180051561A (ko) 2018-05-16
HUE062511T2 (hu) 2023-11-28
EP3347002A4 (en) 2019-04-24
WO2017044840A1 (en) 2017-03-16
SI3347002T1 (sl) 2023-12-29
US11191742B2 (en) 2021-12-07
ES2952727T3 (es) 2023-11-03
AU2016319107B2 (en) 2021-02-25
HRP20230809T1 (hr) 2023-10-27
KR20220042480A (ko) 2022-04-05
CN116712423A (zh) 2023-09-08
RS64481B1 (sr) 2023-09-29
JP2020200352A (ja) 2020-12-17
PT3347002T (pt) 2023-07-27
PL3347002T3 (pl) 2023-11-13
JP6789579B2 (ja) 2020-11-25
MD3347002T2 (ro) 2023-10-31
CA2997376A1 (en) 2017-03-16
LT3347002T (lt) 2023-09-11
US20220096406A1 (en) 2022-03-31
CA2997376C (en) 2024-05-14
EP3347002B1 (en) 2023-06-07
KR102547164B1 (ko) 2023-06-22
CN116712422A (zh) 2023-09-08
KR102412997B1 (ko) 2022-06-23
EP3347002A1 (en) 2018-07-18
US20230414541A1 (en) 2023-12-28
CN108289870A (zh) 2018-07-17
JP7128536B2 (ja) 2022-08-31
AU2016319107A1 (en) 2018-03-22
JP2022145949A (ja) 2022-10-04
MX2018003023A (es) 2018-06-06
EP4275750A2 (en) 2023-11-15
FI3347002T3 (fi) 2023-08-10

Similar Documents

Publication Publication Date Title
MX2022003128A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
MX2021009830A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
PH12019501095A1 (en) (aza)indole-,benzothiopene-, and benzofuran-3-sulfonamides
MX2021012547A (es) Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
PH12018501288A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
WO2015143447A3 (en) Methods for treating neurological disorders
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
BR112016018170A2 (pt) métodos para tratar doença de alzheimer
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
EA201370008A1 (ru) Лечение когнитивных нарушений
EP3377118A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3052137A4 (en) Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
HK1257666A1 (zh) 使用pm20d1和n-脂化氨基酸來識別、評估、預防和治療代謝紊亂的方法
MX2017006692A (es) Trastornos neurodegenerativos.
MX2017003892A (es) Tratamiento del sindrome de rett.
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
MX2018004380A (es) Compuestos de aminotiolesteres o sus sales farmaceuticamente aceptables para usarse en el tratamiento del cancer.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders